(Q53576534)

15 May 2018

title

Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. (English)

1 reference

15 May 2018

0 references

0 references

Mavissakalian MR

1

1 reference

15 May 2018

Perel JM

series ordinal

2

1 reference

15 May 2018

Talbott-Green M

series ordinal

3

1 reference

15 May 2018

Sloan C

series ordinal

4

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 June 1998

1 reference

15 May 2018

published in

Biological Psychiatry

1 reference

15 May 2018

volume

43

1 reference

15 May 2018

page(s)

848-854

1 reference

15 May 2018

issue

11

1 reference

15 May 2018

An Inventory for Measuring Depression

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Untreated anxiety among adult primary care patients in a Health Maintenance Organization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Determination of imipramine, desipramine and their hydroxy metabolites by reversed-phase chromatography with ultraviolet and coulometric detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

A rating scale for depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Differences in the mix of patients among medical specialties and systems of care. Results from the medical outcomes study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Brief standard self-rating for phobic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Combined pharmacological and behavioral treatment for agoraphobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Group cognitive-behavioral treatment of panic disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Determination of clomipramine and desmethylclomipramine in plasma by means of liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

Treatment of Agoraphobia With Group Exposure In Vivo and Imipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900376-4

10.1016/S0006-3223(97)00376-4

7 January 2021

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

9611676

1 reference

15 May 2018